Compare Steel Dynamics Inc. (STLD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Steel Dynamics Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Steel Dynamics Inc. trades at $244.39 (market cap $34.49B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Steel Dynamics Inc. is far larger — about 4.6× Spyre Therapeutics Inc. Common Stock's market cap, and Steel Dynamics Inc. pays a 0.88% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Steel Dynamics Inc. for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| STLD | SYRE | |
|---|---|---|
Market Cap | $34.49B | $7.52B |
Volume | 688,362 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $282.76 | $108.92 |
52-Week Low | $142.65 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $38.10B | $6.52B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Steel Dynamics (STLD) trades at $240.63, up 0.62% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, including a 7.83% net income margin and 17.58% ROE, with Q3 2026 earnings expected at $5.41 EPS. Recent news highlights anticipation for the upcoming earnings report on October 19, 2026.
The outlook is positive, supported by analyst consensus of a $271.17 price target and 'Moderate Buy' ratings. Risks include earnings volatility and steel market cyclicality, but revenue growth to $20.5B in 2026 and solid cash flow provide a foundation for potential upside.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Steel Dynamics Inc.
Steel Dynamics produces steel, processes recycled metals, and provides steel-fabrication services. Its operations use recycled scrap as a key input and also include aluminum products.
Read more on STLD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
